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A B S T R A C T
The pathophysiology, structural and functional changes in diastolic heart failure are 
characterized by the lack of ventricular dilatation, normal left ventricular ejection 
fraction and increased fibrosis and left ventricular stiffness. The hemodynamic profile 
is similar to that of systolic heart failure. The therapeutic modalities available remain 
limited. Current data on diastolic heart failure are herein briefly reviewed.
D E F I N I T I O N
Several definitions of diastolic heart failure have been proposed.1-5 One defini-
tion is, “a condition resulting from an increased resistance to filling of one or both 
ventricles leading to symptoms of congestion due to an inappropriate upward shift of 
the diastolic pressure –volume relation (that is during the terminal phase of the car-
diac cycle)”. Another proposed definition is that diastolic heart failure is a condition 
in which the “ventricular chamber is unable to accept an adequate volume of blood 
during diastole at normal diastolic pressures and at volumes sufficient to maintain an 
appropriate stroke volume”. These definitions describe pathophysiology and functional 
abnormalities but cannot be applied in clinical practice.
The widely used clinical definition of diastolic heart failure is, “a clinical condition 
characterized by the presence of signs and symptoms of heart failure and preserved 
left ventricular ejection fraction”. Based on this definition, diastolic heart failure is 
also termed “heart failure with preserved ejection fraction”.
R E M O D E L I N G
In diastolic heart failure, left ventricular (LV) cavity size is normal or decreased.3-8 
End-diastolic volume remains normal or even decreased. End-systolic volume is usually 
smaller and therefore ejection fraction is normal. Left ventricular dilatation does not 
occur without ischemic myocyte necrosis. Left ventricular wall thickness and mass is 
increased. The cavity/mass ratio is decreased.
Left ventricular hypertrophy is uniformly present. The myocyte diameter is 
increased but its length remains normal, thus the myocyte length/width ratio is 
decreased. The sarcomeres are replicated in parallel. There are also considerable 
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changes in the matrix. The collagen volume is substantially 
increased. There is increased width and continuity of fibril-
lar collagen. Collagen cross-links are increased. In general, 
the matrix metallo-proteinases levels are decreased and their 
endogenous tissue inhibitors are increased in diastolic heart 
failure. The titin isoforms N2BA/N2B ratio is increased in 
diastolic heart failure.
F U N C T I O N A L  C H A N G E S
Increased LV passive stiffness and impaired LV relaxa-
tion is the principal functional abnormality in diastolic heart 
failure.1-5 The diastolic pressure-volume relation shifts upward 
and to the left which is associated with a disproportionately 
greater increase in diastolic pressure for any increase in vol-
ume.
In advanced diastolic heart failure, LV end-diastolic pres-
sure may exceed 20-25 mmHg which may cause pulmonary 
congestion and dyspnea. There is also a passive increase in 
pulmonary venous pressure which is associated with post-
capillary pulmonary hypertension. Chronic increase in pul-
monary venous pressure frequently causes mixed pulmonary 
hypertension. Because of pulmonary hypertension, right heart 
failure ensues with its signs and symptoms such as peripheral 
edema, hepatomegaly and even secondary tricuspid regurgita-
tion. If there is also marked restriction of ventricular filling, 
stroke volume and cardiac output is decreased without any 
change in contractile function and ejection fraction. Thus, 
in advanced diastolic heart failure, the hemodynamic profile 
may be similar to those of severe systolic heart failure. The 
structural and functional changes in diastolic heart failure are 
summarized in Table 1.
D O E S  T H E  L E F T  V E N T R I C L E  D I L A T E  
I N  D I A S T O L I C  H E A R T  F A I L U R E ?
There are controversies about changes in LV function and 
morphology in diastolic heart failure.3-6 Some authorities have 
hypothesized that the left ventricle can dilate significantly 
along with reduced ejection fraction. However, recent stud-
ies have demonstrated that during an average of 64 months 
of follow-up, in patients with diastolic heart failure without 
coronary artery disease, LV volumes and ejection fraction 
remain unchanged. The LV end-diastolic pressures and stiff-
ness increase, suggesting that LV diastolic function worsens 
in these patients.
T H E R A P E U T I C  O P T I O N S
Unlike systolic heart failure, there has been very little 
progress in the management of diastolic heart failure.1,3,9 For 
the relief of congestive symptoms, diuretics and nitrates are 
necessary. However, excessive diuretic or nitrate therapy may 
be associated with inappropriate reduction of preload and 
cardiac output and hypotension.
To maintain appropriate time for ventricular filling, the 
heart rate needs to be controlled either pharmacologically or 
by pacemaker therapy. It is desirable to maintain sinus rhythm 
in diastolic heart failure to maintain adequate stroke volume 
and cardiac output.
To decrease mortality or morbidity, very few pharmaco-
logic events have been evaluated. The “CHARM Preserved”9 
trial has reported that the angiotensin receptor blocking 
agent candesartan may decrease hospital admission rates. It 
should be emphasized that non-pharmacologic therapy, such 
as chronic resynchronization with or without defibrillator 
therapy, has not been shown to provide any benefit.10
It is apparent that further research and investigations are 
required to determine potential beneficial therapies for treat-
ment of diastolic heart failure. There is, however, extensive 
research being undertaken to discover potential new and 
effective therapeutic agents for treatment of diastolic heart 
failure (Table 2).
TABLE 1. The structural and functional changes in diastolic 
heart failure.
Parameters Diastolic heart failure
LV end-diastolic volume Normal or decreased
LV end-systolic volume Normal or decreased
Ejection fraction Normal
LV mass Increased
LV wall thickness Increased
LV end-systolic stress Normal
LV end-diastolic stress Increased
Mechanical dyssynchrony May be present
LV shape and geometry Usually unchanged
Myocyte hypertrophy Present
Myocardial fibrosis Present
Calcium regulation Abnormal
MMPs/TIMPs Decreased
Collagen cross links Increased
Titin isoforms N2BA/N2B Decreased
LV = left ventricular; MMPs = matrix metalo-proteinases;  
TIMPs = tissue inhibitors of metalo-proteinases
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C O N C L U S I O N S
The pathophysiology, remodeling and functional changes 
in diastolic heart failure are characterized by the lack of 
ventricular dilatation, normal ejection fraction and increased 
fibrosis and left ventricular stiffness. The hemodynamic pro-
file is similar to that of systolic heart failure. The therapeutic 
modalities available are limited. Further and continued re-
search is necessary to discover new and effective treatment 
of this syndrome, which is associated with poor prognosis 
particularly in advanced diastolic heart failure.
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TABLE 2. Potential new therapies for diastolic heart fail-
ure.
To decrease myocardial fibrosis
Aldosterone antagonists
Angiotensin inhibition
Chymase antagonists
TGF –beta
To improve relaxation
Phospholamban inhibitors
D- ribose
Modulation of collagen cross-links
Modulation of Titin isoforms
Modulation of MMPs/TIMPs
MMPs = metalo-proteinases; TIMPs = tissue inhibitors of metalo-
proteinases; TGF = transforming growth factor
